Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRG50635 in sporadic and familial ALS
NCT06215755Phase 1Terminated
- Sponsor
- Verge Genomics
- Start
- Jan 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of VRG50635 in amyotrophic lateral sclerosis (ALS), sponsored by Verge Genomics. Primary endpoints: Treatment-emergent Adverse Events at 80 weeks, Clinical Laboratory Evaluation Abnormalities at 80 weeks and 4 more. Started Jan 2024; status: terminated.
02
Drugs
VRG50635
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06215755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06215755.